
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
? TAKHZYRO Approved for Adult and Pediatric Patients 12 Years of Age and Older1 ? Approval Based on Results of Global Phase 3 HELP Study™, […]

